Uncovering the Latest Evidence in MS and its Implications for Clinical Practice

Uncovering the Latest Evidence in MS and its Implications for Clinical Practice is organized by Prime Education, LLC.

Release Date: June 7, 2019
Expiration Date: June 6, 2020

Intended Audience:
Physicians, Nurse Practitioners, Physician Assistants, Nurses, Pharmacists, and Case Managers

Accreditation:
Continuing Education Credits:
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credits for learning and change.

Physician Credit Designation Statement
PRIME designates this Enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Physician Assistant Accreditation Statement
This program has been reviewed and is approved for a maximum of 1.0 hour of AAPA Category I CME credit by the Physician Assistant Review Panel. Physician assistants should claim only those hours actually spent participating in the CME activity.

Nurse Practitioner Accreditation Statement
This activity is approved for 1.0 contact hour of continuing education by the American Association of Nurse Practitioners. This activity was planned in accordance with AANP Accreditation Standards and Policies

Pharmacist Accreditation Statement
This curriculum has been approved for 1.0 contact hour (0.1 CEUs) by PRIME.

Nurse Accreditation Statement
PRIME designates this activity for 1.0 contact hour.

Case Manager Accreditation Statement
The Commission for Case Manager Certification designates this educational activity for 1.0 contact hour for certified case managers. Credits for this program are pre-approved.

 

Description:
In this dynamic CE-accredited video activity, renowned multiple sclerosis (MS) experts examine the latest evidence presented at recent meetings, including clinical data on new and emerging disease-modifying therapies (DMTs), advances in prognostic indicators to predict clinical course and response to treatment, and shifting paradigms in the management of progressive disease. Discussions will highlight practical applications of recent developments for personalizing care for patients with relapsing and progressive MS.